Recent Updates
Recently added Catalysts
AMGN Neutral Sentiment Score: 60/100

AMGEN ANNOUNCES WEBCAST OF 2023 FIRST QUARTER FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Thursday, April 27, 2023, after the close of the U.S....

Key Takeaway: Amgen has announced that it will release its first quarter financial results on April 27, 2023, after the U.S. financial markets close. This announcement will be accompanied by a conference call scheduled for 1:30 PM PT, featuring CEO Robert A. Bradway and other members of the senior management team. The conference call will be broadcast live over the internet and will be accessible to the media, investors, and the general public. Additionally, the webcast will be archived for at least 90 days for later access.

Market Sentiment Analysis

POSITIVE FACTORS

  • Amgen is reporting its first quarter financial results on April 27, 2023.
  • The financial results announcement will be followed by a conference call with senior management, providing transparency.
  • The webcast will be available for replay for at least 90 days, ensuring accessibility.

Full Press Release Details

THOUSAND OAKS, Calif. , April 21, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its first quarter financial results on Thursday, April 27, 2023 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 1:30 p.m. PT . Participating in the call from Amgen will be Robert A. Bradway , chairman and chief executive officer, and other members of Amgen's senior management team.
Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.
The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2022, Amgen was named one of the "World's Best Employers" by Forbes and one of "America's 100 Most Sustainable Companies" by Barron's.
CONTACT: Amgen, Thousand Oaks Jessica Akopyan , 805-440-5721 (media) Megan Fox , 805-447-1423 (media) Arvind Sood , 805-447-1060 (investors)

21 %

Frequently Asked Questions

When will Amgen report its Q1 financial results?

Amgen will report its first quarter financial results on April 27, 2023.

What time is Amgen's conference call on Q1 results?

The conference call will be held at 1:30 p.m. PT on April 27, 2023.

Where can I find the webcast of Amgen's conference call?

The webcast will be available on Amgen's website under the Investors section.

How long will the conference call webcast be available for replay?

The webcast will be archived and available for replay for at least 90 days.

What is Amgen's focus in biotechnology?

Amgen focuses on developing innovative therapeutics for serious illnesses.

Last updated: Apr 21, 2023